Evidence map›Paper›PMID 36844209›Full record

ArticleFrontiers in medicine2023

Persistence of inflammatory and vascular mediators 5 months after hospitalization with COVID-19 infection.

James Melhorn, Asma Alamoudi, Alexander J Mentzer, Emily Fraser, Anastasia Fries, Mark Philip Cassar, Andrew Kwok, Julian Charles Knight, Betty Raman, Nick P Talbot and 1 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
2.3field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 12 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Pathogenic mechanisms of cardiovascular damage in COVID-19.Molecular medicine (Cambridge, Mass.) · 2024
    Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 2 countries.

James MelhornNuffield Department of Clinical Medicine (NDM), University of Oxford, Oxford, United Kingdom.
Asma AlamoudiDepartment of Physiology, Anatomy and Genetics, University of Oxford, Oxford, United Kingdom.
Alexander J MentzerNuffield Department of Clinical Medicine (NDM), University of Oxford, Oxford, United Kingdom.
Emily FraserOxford University Hospitals (OUH) NHS Foundation Trust, Oxford, United Kingdom.
Anastasia FriesNuffield Department of Clinical Medicine (NDM), University of Oxford, Oxford, United Kingdom.
Mark Philip CassarOxford University Hospitals (OUH) NHS Foundation Trust, Oxford, United Kingdom.
Andrew KwokNuffield Department of Clinical Medicine (NDM), University of Oxford, Oxford, United Kingdom.
Julian Charles KnightNuffield Department of Clinical Medicine (NDM), University of Oxford, Oxford, United Kingdom.
Betty RamanOxford University Hospitals (OUH) NHS Foundation Trust, Oxford, United Kingdom.
Nick P TalbotOxford NIHR Biomedical Research Centre, University of Oxford, Oxford, United Kingdom.
Nayia PetousiNuffield Department of Clinical Medicine (NDM), University of Oxford, Oxford, United Kingdom.
University of Oxford · GBOxford University Hospitals NHS Trust · GBChinese Academy of Medical Sciences & Peking Union Medical College · CN

Funding

British Heart Foundation RE/18/3/34214Medical Research Council MR/X000974/1Wellcome Trust 204969/Z/16/Z
6 · The paper itself

Abstract

Background and aim: In acute severe COVID-19, patients present with lung inflammation and vascular injury, accompanied by an exaggerated cytokine response. In this study, our aim was to describe the inflammatory and vascular mediator profiles in patients who were previously hospitalized with COVID-19 pneumonitis, months after their recovery, and compare them with those in patients recovering from severe sepsis and in healthy controls. Methods: A total of 27 different cytokine, chemokine, vascular endothelial injury and angiogenic mediators were measured in the plasma of forty-nine patients 5.0 ± 1.9 (mean ± SD) months after they were hospitalized with COVID-19 pneumonia, eleven patients 5.4 ± 2.9 months after hospitalization with acute severe sepsis, and 18 healthy controls. Results: Compared with healthy controls, IL-6, TNFα, SAA, CRP, Tie-2, Flt1, and PIGF were significantly increased in the post-COVID group, and IL-7 and bFGF were significantly reduced. While IL-6, PIGF, and CRP were also significantly elevated in post-Sepsis patients compared to controls, the observed differences in TNFα, Tie-2, Flt-1, IL-7 and bFGF were unique to the post-COVID group. TNFα levels significantly correlated with the severity of acute COVID-19 illness (spearman's r = 0.30, Conclusion: A unique inflammatory and vascular endothelial damage mediator signature is found in plasma months following acute COVID-19 infection. Further research is required to determine its pathophysiological and clinical significance.

Indexed as

COVID-19cytokinesinflammationpost-COVIDvascular injury

Identifiers

PMID36844209
PMCPMC9950100
OpenAlexW4319984580

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.